• Capricor Therapeutics is trading at $6.32 (-7.52%) ahead of the FDA’s August 22, 2026 Deramiocel decision, following a previous 9-3 vote by advisers against its effectiveness.
  • New securities-fraud class actions were announced today, August 21, 2026, alleging misleading statements about Deramiocel’s clinical-data analysis and FDA pathway.
  • Activist investor Kaos Capital also announced on August 21, 2026, it is pushing for an urgent board meeting and changes to the company's strategic direction.